BCR gene fused ABL kinase is the critical driving force for the Philadelphia Chromosome positive (Ph+) Chronic Myeloid Leukemia (CML) and has been extensively explored as a drug target. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.